Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment. The Company develops and manufactures a range of dialysis machines, systems and disposable products. As of December 31, 2016, the Company sold its products to customers in more than 120 countries and also used in its internal healthcare service operations. The Company's Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, ambulatory surgery center services and urgent care services.
As of December 31, 2016, the Company provides dialysis treatment and related laboratory and diagnostic services through its global network of over 3,600 outpatient dialysis clinics. At its clinics, it provides hemodialysis (HD) treatments at individual stations through the use of dialysis machines and disposable products. As part of the dialysis therapy, the Company provides a range of services to ESRD patients at its dialysis clinics in the United States. These services include administering erythropoietin stimulating agents (ESAs), which are synthetic engineered hormones that stimulate the production of red blood cells. The Company's clinics also offer services for home dialysis patients. It provides materials, training and patient support services, including clinical monitoring, follow-up assistance and arranging for delivery of the supplies to the patient's residence. The Company also provides dialysis services under contract to hospitals in the United States on an as needed basis for hospitalized ESRD patients and for patients suffering from acute kidney failure.
The Company is a manufacturer and distributor of equipment and related products for hemodialysis. The Company is also a manufacturer and distributer of peritoneal dialysis (PD) products. The Company supplies dialysis products to its dialysis clinics. The Company produces and distributes a range of machines and disposables for HD, PD and acute dialysis. As of December 31, 2016, its line of hemodialysis machines included three series. The Company has developed the 4008 and 5008 Series for its markets outside of North America and the 2008 Series for the North American market. The Company also offers 6008 CAREsystem.
The Company offers dialyzers, which are filters that remove waste products, toxins and excess water from the blood during dialysis. The Company is a producer of polysulfone dialyzers. The Company manufactures its F-Series and FX class series of dialyzers and its Optiflux polysulfone single-use dialyzer using hollow fiber Fresenius Polysulfone and Helixone membranes from synthetic materials. The Company's FX CorDiax dialyzer contains the Helixone plus high performance membrane. The Helixone plus membrane filters out toxins, such as phosphates. The Company offers a range of peritoneal dialysis systems and solutions for both continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) treatments. The stay safe system is designed to help patients with their daily self-care CAPD treatment. Its PD stay safe balance and stay safe bicaVera solutions reduce the advanced glycation end product (AGE) formation. The Company also offers sleep safe cycler, sleep safe harmony cycler and Liberty cycler for PD patients.
The Company develops and in-licenses renal pharmaceuticals. The Company offers PhosLo, a calcium-based phosphate binder; Velphoro, an iron-based phosphate binder; Venofer; Ferinject; OsvaRen, and Phosphosorb. The Company provides general testing, clinical anatomic pathology and molecular testing for healthcare providers in the New York region. The Company offers pharmacy services, mainly in the United States. These services include providing renal medications and supplies to the homes of patients or to their dialysis clinic directly from renal pharmacists. It operates vascular access centers mainly in the United States.
The Company competes with DaVita HealthCare Partners, Inc., U.S. Renal Care, Inc., Diaverum S.a r.l., Kuratorium fur Heimdialyse, Showa-Kai, Baxter International Inc., Asahi Kasei Medical Co. Ltd., Medtronic Plc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co., Ltd., NxStage Medical, Inc., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd. and Toray Industries, Inc.
Else-Kroener-Strasse 1
The company trades on NYSE exchange. The company headquarter is located in Germany. The company was established in the 1996.| Ticker | FMS |
| Long Name | Fresenius Medical Care Corporation |
| Short Name | Fresenius Medical Care |